Rossari Biotech Q3 Results 2025 on 22 Jan, 2025: profit falls by 7.82% YOY, profit at ₹31.7 crore and revenue at ₹512.73 crore | Company Business News

Rossari Biotech Q3 Results 2025:Rossari Biotech declared their Q3 results on 21 Jan, 2025, revealing a mixed performance for the quarter. The company’s revenue increased by 10.56% year-over-year (YoY), reaching ₹512.73 crore. However, profit saw a decline of 7.82% YoY, totaling ₹31.7 crore.

In comparison to the previous quarter, Rossari’s revenue grew by 2.89%, while profit decreased by 10.27%. This decline in profit is attributed to rising operational costs, as the Selling, General & Administrative expenses rose by 9.61% quarter-over-quarter (q-o-q) and 37.06% YoY.

The operating income also faced challenges, down by 8.53% q-o-q and 4.38% YoY. The Earnings Per Share (EPS) for Q3 was reported at ₹5.72, reflecting a decrease of 7.89% YoY.

Rossari Biotech has experienced a -3.55% return in the last week, a -0.42% return over the past six months, and a 3.24% year-to-date return.

Currently, Rossari Biotech holds a market capitalization of ₹4441.79 crore, with a 52-week high of ₹972.7 and a low of ₹656.95.

As of 22 Jan, 2025, out of five analysts covering the company, one analyst has given a Hold rating, while four analysts have recommended a Strong Buy. The consensus recommendation for Rossari Biotech as of the same date is to Strong Buy.

Rossari Biotech Financials

Period	Q3 (FY25)	Q2 (FY25)	Q-o-Q Growth	Q3 (FY24)	Y-o-Y Growth
Total Revenue	512.73	498.35	+2.89%	463.77	+10.56%
Selling/ General/ Admin Expenses Total	35.69	32.56	+9.61%	26.04	+37.06%
Depreciation/ Amortization	18.32	15.16	+20.84%	15.09	+21.4%
Total Operating Expense	466.29	447.57	+4.18%	415.19	+12.31%
Operating Income	46.45	50.78	-8.53%	48.58	-4.38%
Net Income Before Taxes	42.38	48.11	-11.91%	47.78	-11.3%
Net Income	31.7	35.33	-10.27%	34.39	-7.82%
Diluted Normalized EPS	5.72	6.38	-10.34%	6.21	-7.89%